An economic evaluation of dasatinib as a treatment for chronic phase chronic myeloid leukaemia in Scotland

被引：1
|
作者：
Taylor, M. J. [1 ]
Minda, K. [2 ]
Cerri, K. H. [3 ]
Davis, C. [4 ]
Kan, H. J. [4 ]
Ray, S. [2 ]
机构：
[1] Univ York, York YO10 5DD, N Yorkshire, England
[2] Bristol Myers Squibb Pharmaceut, Uxbridge, Middx, England
[3] Bristol Myers Squibb Co, New York, NY 10154 USA
[4] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
来源：
VALUE IN HEALTH | 2007年 / 10卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)64889-9
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A233 / A233
页数：1
相关论文
共 50 条
  • [1] AN ECONOMIC EVALUATION OF DASATINIB FOR THE TREATMENT OF IMATINIB RESISTANT PATIENTS WITH ADVANCED PHASE CHRONIC MYELOGENOUS LEUKAEMIA
    Taylor, M.
    Lewis, L.
    Lebmeier, M.
    Wang, Q.
    VALUE IN HEALTH, 2011, 14 (03) : A167 - A167
  • [2] REVERSIBLE LYMPH NODE FOLLICULAR HYPERPLASIA ASSOCIATED WITH DASATINIB TREATMENT FOR CHRONIC MYELOID LEUKAEMIA IN CHRONIC PHASE
    Roux, C.
    Nicolini, F.
    Rea, D.
    Niault, M.
    Mollica, L.
    Berger, F.
    Chassagne-clement, C.
    Tigaud, I.
    Rousselot, P.
    Legros, L.
    HAEMATOLOGICA, 2013, 98 : 302 - 303
  • [3] Efficacy and tolerability of dasatinib as a second line therapy for chronic myeloid leukaemia in the west of Scotland
    Irvine, D. A.
    Drummond, M. W.
    Holyoake, T. L.
    Wilson, G.
    Stewart, K.
    Gillespie, L.
    Copland, M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 : 84 - 84
  • [4] THE INCIDENCE AND NATURAL HISTORY OF DASATINIB COMPLICATIONS IN THE TREATMENT OF CHRONIC MYELOID LEUKAEMIA
    Fox, L.
    Putt, F.
    Yeung, D.
    Carne, L.
    Cleary, R.
    Cummins, K.
    Fleming, S.
    Forsyth, C.
    Dixon, M.
    Tatarczuch, M.
    Motorna, O.
    Janowski, W.
    Hughes, M.
    McQuillan, A.
    Schwarer, A.
    Devos, J.
    Harrup, R.
    Holmes, A.
    Ratnasingam, S.
    Chan, K. L.
    Hsu, B.
    Bury, K.
    Grigg, A.
    HAEMATOLOGICA, 2016, 101 : 236 - 237
  • [5] Dasatinib Treatment for Imatinib Resistant or Intolerant Patients with Chronic Myeloid Leukaemia
    Li, J.
    Xu, G.
    Yu, S.
    He, L.
    Guo, L.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2011, 39 (02) : 337 - 347
  • [6] An audit of the use of imatinib in the treatment of chronic myeloid leukaemia in Scotland
    Johnson, PRE
    Dhanapala, C
    Maguire, C
    White, J
    Drummond, M
    Shepherd, PCA
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 : 17 - 17
  • [7] Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation
    Rogers, G.
    Hoyle, M.
    Coon, J. Thompson
    Moxham, T.
    Liu, Z.
    Pitt, M.
    Stein, K.
    HEALTH TECHNOLOGY ASSESSMENT, 2012, 16 (22) : 1 - +
  • [8] COST-UTILITY ANALYSIS OF DASATINIB AS A SECOND-LINE TREATMENT IN THE CHRONIC PHASE OF CHRONIC MYELOID LEUKAEMIA IN RUSSIA
    Kuznetzov, S.
    Mungapen, L. J.
    Samyshkin, Y.
    Jakouloff, D. E.
    Sbarigia, U.
    van Baardewijk, M.
    VALUE IN HEALTH, 2010, 13 (07) : A270 - A270
  • [9] ECONOMIC EVALUATION OF DASATINIB IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA IN PATIENTS RESISTANT TO IMATINIB IN CHILE
    Orozco, J. J.
    Valencia, J. E.
    Aiello, E.
    Caputo, M.
    VALUE IN HEALTH, 2011, 14 (07) : A543 - A543
  • [10] Economic evaluation of dasatinib in the treatment of chronic myeloid leukemia in patients resistant to imatinib in Chile
    Orozco Giraldo, John Jairo
    Valencia, Juan Esteban
    Aiello, Eleonora
    Caputo, Milva
    MEDWAVE, 2011, 11 (04):
12345